Optimal radiotherapy utilisation rate in developing countries: An IAEA study

Rosenblatt E 1 , Barton M 2 , Mackillop W 3 , Fidarova E 1 , Cordero L 4 , Yarney J 5 Show all authors , Lim G 6 , Abad A 7 , Cernea V 8 , Stojanovic-Rundic S 9 , Strojan P 10 , Kobachi L 11 , Quarneti A 12

Affiliations 

  • 1 International Atomic Energy Agency, Nuclear Applications, Vienna, Austria
  • 2 Ingham Institute for Applied Medical Research, Radiation Oncology, Sydney, Australia. Electronic address: michael.barton@sswahs.nsw.gov.au
  • 3 Queen's Cancer Research Institute, Queen's University, Kingston, Canada
  • 4 Hospital Mexico, Radiotherapy, San Jose, Costa Rica
  • 5 National Centre for Radiotherapy and Nuclear Medicine, Radiotherapy, Accra, Ghana
  • 6 National Cancer Institute, Putrajaya, Malaysia
  • 7 Lung Center of the Philippines Hospital, Radiation Oncology, Quezon City, Philippines
  • 8 Radiation Oncology, Oncology Institute Cluj-Napoca, University of Medicine And Pharmacy, Cluj-Napoca, Romania
  • 9 Institute of Oncology and Radiology of Serbia, Radiation Oncology, Belgrade, Serbia
  • 10 Institute of Oncology, Radiation Oncology, Ljubljana, Slovenia
  • 11 Institut National de Cancer Salah Azaiz, Radiotherapy, Tunis, Tunisia
  • 12 Hospital Pereira Rossell, Radiotherapy, Montevideo, Uruguay
Radiother Oncol, 2015 Jul;116(1):35-7.
PMID: 26164776 DOI: 10.1016/j.radonc.2015.06.012

Abstract

Optimal radiotherapy utilisation rate (RTU) is the proportion of all cancer cases that should receive radiotherapy. Optimal RTU was estimated for 9 Middle Income Countries as part of a larger IAEA project to better understand RTU and stage distribution.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications